Human Investing LLC Decreases Stake in Novo Nordisk A/S (NYSE:NVO)

Human Investing LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 3.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,006 shares of the company’s stock after selling 867 shares during the quarter. Novo Nordisk A/S comprises 0.3% of Human Investing LLC’s investment portfolio, making the stock its 29th largest position. Human Investing LLC’s holdings in Novo Nordisk A/S were worth $1,893,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Natixis Advisors LLC increased its position in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares during the period. Versant Capital Management Inc bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $86,000. Talbot Financial LLC bought a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $4,066,000. Finally, Clear Creek Financial Management LLC bought a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $450,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 1.1 %

Shares of NYSE NVO opened at $77.94 on Monday. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $349.75 billion, a PE ratio of 23.69, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $77.82 and a 12-month high of $148.15. The stock’s fifty day simple moving average is $88.65 and its two-hundred day simple moving average is $109.70.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts expect that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 21.88%.

Analysts Set New Price Targets

NVO has been the topic of a number of recent research reports. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.